Cancel
Allergic Rhinitis
AR
Allergic rhinitis (AR) (commonly referred to as Hay Fever) is a seasonal allergic respiratory condition largely driven by inflammation mediated by allergens. The most common allergens are pollens, dust mites, moulds, and insects, which when inhaled result in sneezing, itching, airflow obstruction (wheezing), and rhinorrhoea (a runny nose).
AR often co-exists with other conditions such as asthma, sinusitis, nasal polyposis, upper respiratory tract infections, middle ear infections, sleep disorders, and impaired learning and attention in children.
AR therapy is based on allergen avoidance, and the administration of anti-allergic and anti-inflammatory drugs (e.g., antihistamines, corticosteroids). Allergen-specific immunotherapy for induction of tolerance is a potential treatment option, however availability of this treatment may be limited. Patient dissatisfaction has been identified in AR surveys indicating the need for new treatment options.
Allergic Rhinitis
AR
Allergic rhinitis (AR) (commonly referred to as Hay Fever) is a seasonal allergic respiratory condition largely driven by inflammation mediated by allergens. The most common allergens are pollens, dust mites, moulds, and insects, which when inhaled result in sneezing, itching, airflow obstruction (wheezing), and rhinorrhoea (a runny nose).
AR often co-exists with other conditions such as asthma, sinusitis, nasal polyposis, upper respiratory tract infections, middle ear infections, sleep disorders, and impaired learning and attention in children.
AR therapy is based on allergen avoidance, and the administration of anti-allergic and anti-inflammatory drugs (e.g., antihistamines, corticosteroids). Allergen-specific immunotherapy for induction of tolerance is a potential treatment option, however availability of this treatment may be limited. Patient dissatisfaction has been identified in AR surveys indicating the need for new treatment options.
Key AR Figures
$15B+
with AR
≤
30%
population with AR
40%
≥ 40%
Key AR Figures
$15B+
pop. with AR
≤ 30%
pop. with AR
40%
≥ 40%
Mechanism of Action
The mechanism of action of PPS relevant to the treatment of AR is the:
- Inhibition of TH2 (T helper 2) cytokines involved in the development of allergic responses.
Allergen
Development milestones
Preclinical studies performed at Lund University, Sweden demonstrated that intranasal delivered PPS inhibited AR in a validated Guinea pig model.
Paradigm is considering the potential of second-generation PPS molecules to address the therapeutic efficacy in this disease state.
For more information and updates, please see our ASX announcements.
